We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Magnetic Resonance Spectroscopy in Autonomic Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01607268
Recruitment Status : Terminated (Could not enroll enough participants, and lost funding.)
First Posted : May 30, 2012
Last Update Posted : January 18, 2017
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
This research study will be conducted in patients with primary autonomic failure, a disabling condition that is associated with low blood pressure upon standing. These patients are also not able to control for changes in their blood pressure due to a loss of cardiovascular reflexes that are mediated within the brain. The purpose of this study is to determine whether magnetic resonance spectroscopy (MRS), a non-invasive imaging technique, can measure levels of chemicals (neurotransmitters) in the dorsal medulla, a brain area important for control of cardiovascular function, in autonomic failure patients. Importantly, this study will determine whether there are differences in brain chemicals between patients with peripheral versus central origins of their autonomic failure. The hypothesis is that the neurotransmitter profile in the medulla will be intact in patients with peripheral autonomic failure compared to those with central impairment. Overall, this study will provide insight into understanding the mechanisms involved in autonomic failure and will determine whether a single session of MRS imaging can improve the ability to make an accurate diagnosis in these patients. This would lessen the need for more extensive and invasive clinical testing.

Condition or disease Intervention/treatment
Pure Autonomic Failure Multiple System Atrophy Procedure: Magnetic Resonance Spectroscopy Imaging

Study Design

Study Type : Observational
Actual Enrollment : 6 participants
Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Proton Magnetic Resonance Spectroscopy in Primary Autonomic Failure
Study Start Date : July 2012
Primary Completion Date : January 2017
Study Completion Date : January 2017


Groups and Cohorts

Group/Cohort Intervention/treatment
Pure Autonomic Failure
Pure autonomic failure is a type of primary autonomic failure characterized by peripheral autonomic nervous system impairment.
Procedure: Magnetic Resonance Spectroscopy Imaging
Proton magnetic resonance spectroscopy [1H-MRS] is an emerging imaging tool that allows for non-invasive assessment of brain neurochemistry in human subjects. This technique allows for in vivo quantification of the concentration of neurotransmitters and metabolites in discrete brain regions through detection of hydrogen nuclei in these molecules. Autonomic failure patients will undergo a single imaging session lasting 30 to 90 minutes (0.5-1.5 hours) in the Vanderbilt Human Imaging Institute.
Other Name: MRS
Multiple System Atrophy
Multiple system atrophy is a type of primary autonomic failure characterized by central autonomic nervous system impairment.
Procedure: Magnetic Resonance Spectroscopy Imaging
Proton magnetic resonance spectroscopy [1H-MRS] is an emerging imaging tool that allows for non-invasive assessment of brain neurochemistry in human subjects. This technique allows for in vivo quantification of the concentration of neurotransmitters and metabolites in discrete brain regions through detection of hydrogen nuclei in these molecules. Autonomic failure patients will undergo a single imaging session lasting 30 to 90 minutes (0.5-1.5 hours) in the Vanderbilt Human Imaging Institute.
Other Name: MRS


Outcome Measures

Primary Outcome Measures :
  1. N-Acetylaspartate Levels [ Time Frame: 0.5-1.5 hours ]
    Differences in levels of N-acetylaspartate in the dorsal medulla of pure autonomic failure versus multiple system atrophy patients using single session imaging.


Secondary Outcome Measures :
  1. Myoinositol Levels [ Time Frame: 0.5-1.5 hours ]
    Differences in levels of myoinositol in the dorsal medulla pure autonomic failure versus multiple system atrophy patients.

  2. GABA Levels [ Time Frame: 0.5-1.5 hours ]
    Differences in levels of the neurotransmitter GABA in the dorsal medulla of pure autonomic failure versus multiple system atrophy patients.

  3. Creatinine Levels [ Time Frame: 0.5-1.5 Hours ]
    Differences in levels of creatinine-containing compounds in the dorsal medulla of pure autonomic failure versus multiple system atrophy patients.

  4. Choline Levels [ Time Frame: 0.5-1.5 Hours ]
    Differences in levels of choline-containing compounds in the dorsal medulla of pure autonomic failure versus multiple system atrophy patients.

  5. Glutamate Levels [ Time Frame: 0.5-1.5 Hours ]
    Differences in levels of glutamate in the dorsal medulla of pure autonomic failure versus multiple system atrophy patients.


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary autonomic failure patients will be recruited from patients already in the hospital participating in the approved protocol "The Evaluation and Treatment of Autonomic Failure." Prospective participants come from several sources including clinic patients, former patients, referrals from other physicians, and subjects that read about the Autonomic Dysfunction Center on the Vanderbilt website.
Criteria

Inclusion Criteria:

  • Patients with primary autonomic failure who are already participating in the approved Vanderbilt study "Evaluation and Treatment of Autonomic Failure"
  • Males and females of all races between 18 and 80 years of age
  • Able and willing to provide informed consent

Exclusion Criteria:

  • Pregnant women
  • Patients with diagnosed Parkinson's Disease or secondary forms of autonomic failure
  • Patients with severe claustrophobia
  • Patients taking medications known to affect brain neurotransmitter levels [e.g., anti-depressants, barbiturates, benzodiazepines, gabapentin, namenda, sinemet]
  • Patients with implanted medical devices [e.g., pacemakers, metal clips, cochlear implants, orthopedic hardware], lead-based tattoos or pieces of metal close to or in an important organ
  • High-risk patients [e.g., heart failure, symptomatic coronary artery disease, liver impairment, history of stroke or myocardial infarction]
  • Inability to give or withdraw informed consent
  • Other factors which in the investigator's opinion would prevent the subject from completing the protocol including significant abnormalities in clinical, mental, or laboratory testing
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01607268


Locations
United States, Tennessee
Vanderbilt University
Nashville, Tennessee, United States, 37211
Sponsors and Collaborators
Vanderbilt University
Investigators
Principal Investigator: Italo Biaggioni, MD Vanderbilt University
More Information

Additional Information:
Responsible Party: Italo Biaggioni, Professor and Associate Director Clinical Research Center, Vanderbilt University
ClinicalTrials.gov Identifier: NCT01607268     History of Changes
Other Study ID Numbers: 120574
First Posted: May 30, 2012    Key Record Dates
Last Update Posted: January 18, 2017
Last Verified: January 2017

Keywords provided by Italo Biaggioni, Vanderbilt University:
autonomic failure
mangenetic resonance
neurochemistry
neurotransmitter
glutamate

Additional relevant MeSH terms:
Atrophy
Multiple System Atrophy
Shy-Drager Syndrome
Pure Autonomic Failure
Pathological Conditions, Anatomical
Primary Dysautonomias
Autonomic Nervous System Diseases
Nervous System Diseases
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Hypotension
Vascular Diseases
Cardiovascular Diseases
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs